Slides
Page 1
Q3 2026 Earnings Presentation October 28, 2026
Page 2
Forward - Looking Statements This presentation may contain forward - looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those expressed in the forw ard - looking statements herein or in previous disclosures. For example, in addition to general industry and economic conditions, factors t hat could cause actual results to differ materially from those in the forward - looking statements may include, but are not limited to the risk fa ctors discussed in the Company's Annual Report on Form 10 - K for the full year ended December 31, 2025, listed under the heading Forward - Looking Statements in the Company’s most recently filed Form 10 - Q and other risks and uncertainties, which may be detailed from time to time in reports filed by CONMED with the SEC. Any and all forward - looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company’s performance on a going - forward basis. The Company b elieves that all forward - looking statements made by it have a reasonable basis, but there can be no assurance that management’s expectat ions, beliefs or projections as expressed in the forward - looking statements will actually occur or prove to be correct. Management has disclosed adjusted financial measurements in this presentation that present financial information that is not in accordance with generally accepted accounting principles in the United States (GAAP). The Company analyzes net sales on a constant curre ncy basis, organic basis, and organic constant currency basis to better measure the comparability of results between periods. To measure ea rnings performance on a consistent and comparable basis, the Company excludes certain items that affect the comparability of operati ng results and the trend of earnings. These adjustments are irregular in timing, may not be indicative of past and future performance an d a re therefore excluded to allow investors to better understand underlying operating trends. These measurements are not a substitute for GAA P measurements. Investors should consider adjusted measures in addition to, and not as a substitute for, or superior to, finan cia l performance measures prepared in accordance with GAAP. We are unable to present a quantitative reconciliation of our expected diluted net earnings per share to expected adjusted di lut ed net earnings per share, including its components, as we are unable to predict with reasonable certainty and without unreasonable eff ort the impact and timing of acquisition, integration and other charges. The financial impact of these items is uncertain and is depe nde nt on various factors, including timing, and could be material to our consolidated statements of income.
Page 3
CONMED Vision Empower healthcare providers worldwide to deliver exceptional outcomes for patients. Focus behind the Vision People, Products, Profitability
Page 4
Financial Performance Q3 2026 ( 1 ) Growth rates shown versus the three months ended September 30 , 2025 in constant currency . The reconciliation to GAAP numbers is included in our earnings release issued on October 28 , 2026 . ( 2 ) Adjusted diluted EPS excludes the costs of special items, including charges for operational optimization costs, EU medical device regulations (MDR), contingent consideration, termination of distribution agreement, gain on sale of product offering, product rationalization costs, legal matters, and amortization of intangible assets and deferred financing fees, net of tax. ( 3 ) Growth rates shown versus the three months ended September 30 , 2025 in organic constant currency . The reconciliation to GAAP numbers is included in our earnings release issued on October 28 , 2026 . Orthopedics $148.8M General Surgery $186.7M WW Revenue $335.6M International $162.9M Domestic $172.7M Domestic 51%/49% International Capital $49.8M Single - Use $285.7M Single - Use 85%/15% Capital 6.4% 6.7% 7.2% - 6.4% - 0.8% General Surgery Organic Total CNMD Organic Orthopedic Surgery General Surgery Total CNMD 12.8% - 11.0% International Domestic 2.1% - 1.3% Capital Single-Use Revenue $335.6M - 0.7% vs. Q3 2025 as reported - 0.8% vs. Q3 2025 constant currency 6.7% vs. Q3 2025 organic constant currency (3) Diluted EPS Adjusted Diluted Net EPS (2) $0.66 613.7% vs. Q3 2025 $1.04 - 3.2% vs. Q3 2025 Worldwide CC Revenue Growth (1) CC Revenue Growth (1) Worldwide CC Revenue Growth (1) (3) (3)
Page 5
Financial Performance YTD 2026 ( 1 ) Growth rates shown versus the nine months ended September 30 , 2025 in constant currency . The reconciliation to GAAP numbers is included in our earnings release issued on October 28 , 2026 . ( 2 ) Adjusted diluted EPS excludes the costs of special items, including charges for operational optimization costs, product rationalization costs, loss on sale of product offering, EU medical device regulations (MDR), executive transition costs, contingent consideration, gain/loss on early extinguishment of debt (net), termination of distribution agreement, gain on sale of product offering, legal matters, and amortization of intangible assets and deferred financing fees, net of tax. ( 3 ) Growth rates shown versus the nine months ended September 30 , 2025 in organic constant currency . The reconciliation to GAAP numbers is included in our earnings release issued on October 28 , 2026 . Orthopedics $448.8M General Surgery $547.3M WW Revenue $996.1M International $474.9M Domestic $521.2M Domestic 52%/48% International Capital $145.2M Single - Use $850.8M Single - Use 85%/15% Capital 4.0% 5.0% 6.2% - 6.8% - 1.4% General Surgery Organic Total CNMD Organic Orthopedic Surgery General Surgery Total CNMD 7.7% - 8.3% International Domestic 4.2% - 2.3% Capital Single-Use Revenue $996.1M - 0.5% vs. Q3 2025 as reported - 1.4% vs. Q3 2025 constant currency 5.0% vs. Q3 2025 organic constant currency (3) Diluted EPS Adjusted Diluted EPS (2) $1.87 92.5% vs. Q3 2025 $3.31 4.5% vs. Q3 2025 Worldwide CC Revenue Growth (1) CC Revenue Growth (1) Worldwide CC Revenue Growth (1) (3) (3)
Page 6
2026 Financial Guidance Update (1) Organic constant currency revenue excludes the sales of certain gastroenterology ("GI") product offerings for the twelve months ending December 31, 2026 and 2025, related to the Company’s previously announced strategic exits as part of its portfolio optimization strategy. (2) Information reconciling forward - looking adjusted diluted net earnings per share to the comparable GAAP financial measures is una vailable to the company without unreasonable effort, as discussed in the Forward - Looking Statements . (3) “ Prior financial guidance ” reflects the Company’s full year 2026 financial guidance, previously updated on July 29, 2026. Twelve Months Ending December 31, 2026 Dollars in millions, except per share figures Percentages on a year - over - year basis Updated Financial Guidance Prior Financial Guidance (3) Low High Low High Net Sales (GAAP) $1,360 $1,366 $1,358 $1,373 Net Sales Growth, as reported (1.1)% (0.6)% (1.2)% (0.1)% Estimated impact of foreign currency exchange rate fluctuations (0.7)% (0.7)% (0.5)% (0.5)% Net Sales Growth, Constant Currency (1.7)% (1.3)% (1.7)% (0.7)% Estimated impact of strategic product line exits (1) 6.7% 6.8% 6.7% 6.7% Net Sales Growth, Organic, Constant Currency 5.0% 5.5% 5.0% 6.0% Adjusted Diluted Net EPS (2) $4.54 $4.61 $4.48 $4.60 Adjusted Diluted Net EPS Growth (1.2)% 0.4% (2.4)% (0.2)%
Page 7
CONMED Driven to Win ➢ Leveraging Growth Drivers Focusing on high - growth, high - margin products: AirSeal ® , Buffalo Filter ® , BioBrace ® ➢ Optimizing Portfolio Exiting gastroenterology to align resources with minimally invasive surgery, smoke evacuation, and orthopedic soft tissue repair ➢ Transforming Supply Chain Driving supply chain transformation focused on resiliency, predictability, scalability, and efficiency ➢ Strengthening Balance Sheet Enhancing balance sheet to drive growth and shareholder returns
Page 8
View CONMED’s full 2025 Sustainability Report on CONMED.com Partners with the United Way to serve communities where we operate in the U.S. CONMED manufacturing operations have recycling programs including eScrap , metal, cardboard, plastic, and paper. Effective board leadership and independent oversight. 100% independent standing board committees and regular executive sessions of independent directors. Environmental Social Governance 99% of employees participated in the Gallup Q12 Employee Engagement Survey. Committed to maintaining a quality system that provides safe and effective products and services that meet the needs and requirements of our patients, customers, company stakeholders and all regulatory requirements. Use of ISO 14001 and 45001 as a framework to harmonize an Environmental Management System across CONMED. 2025 Sustainability Report includes reporting on the scope 1 and 2 greenhouse gas emissions associated with our operations. CONMED’s first climate - related risks and opportunities disclosure is also included in the report. CONMED’s executive leadership is responsible for setting the ethical code and overseeing compliance. In addition to oversight by the full Board, the Sustainability Steering Committee provides strategic direction and prioritization of social and environmental initiatives. Together we are making a difference for a better tomorrow Sustainability